Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Aged murine bone marrow myeloid and mesenchymal cells develop unique senescence phenotypes
Madison L. Doolittle, Mitchell N. Froemming, Jennifer L. Rowsey, Ming Ruan, Leena Sapra, Joshua N. Farr, David G. Monroe, Sundeep Khosla
Madison L. Doolittle, Mitchell N. Froemming, Jennifer L. Rowsey, Ming Ruan, Leena Sapra, Joshua N. Farr, David G. Monroe, Sundeep Khosla
View: Text | PDF
Research Article Aging Bone biology

Aged murine bone marrow myeloid and mesenchymal cells develop unique senescence phenotypes

  • Text
  • PDF
Abstract

Cellular senescence is a heterogeneous phenotype characterized primarily in mesenchymal cells, but the extent to which immune cells differ in their senescence phenotype, or “senotype,” is unclear. Here, we applied single-cell approaches alongside both global and cell-specific genetic senolytic mouse models to evaluate the senotype of immune cells in the bone marrow of aging mice. We found that myeloid-lineage cells exhibited the highest expression of p16 and senescence-associated secretory phenotype markers among all immune cell types. In contrast with clearance of p16+ senescent mesenchymal cells, targeted clearance of p16+ myeloid cells in aged mice had only minor effects on age-related bone loss in male mice, with no effects in females. In more detailed analyses, p16+ myeloid cells were only acutely cleared, being repopulated back to basal levels within a short time. This led to a lack of long-lasting reduction in senescent cell burden, unlike when targeting bone mesenchymal cells. In vitro, myeloid-lineage cells differed markedly from mesenchymal cells in the development of a senescent phenotype. Collectively, our findings indicate that aged bone marrow myeloid cells do not achieve the fully developed senescent phenotype originally described in mesenchymal cells, justifying further characterization of senotypes of immune cells across tissues.

Authors

Madison L. Doolittle, Mitchell N. Froemming, Jennifer L. Rowsey, Ming Ruan, Leena Sapra, Joshua N. Farr, David G. Monroe, Sundeep Khosla

×

Figure 5

Myeloid cells exhibit divergent senescence characteristics and altered response to senescence induction compared with mesenchymal cells.

Options: View larger image (or click on image) Download as PowerPoint
Myeloid cells exhibit divergent senescence characteristics and altered r...
(A) Representative images of telomere-associated foci (TAF; white arrows) on CD11b+ bone marrow cells from young (6-month-old) and old (24-month-old) wild-type (WT) C57BL/6N mice. N = 10 per age. (B) Quantification of %TAF+ CD11b+ cells subset by the number of TAF observed per cell. (C) Quantification of %TAF+ osteocytes from a previous study from our laboratory (Farr et al., ref. 42; N = 8 per age). (D) Comparisons between %TAF+ subsets between CD11b+ cells and osteocytes. Significance was determined by unpaired t test or Mann-Whitney test, as appropriate. (E) Schematic of in vitro study comparing molecular responses to senescence induction by etoposide between bone marrow–derived macrophages (BMDMs; macrophages) and bone marrow stromal cells (BMSCs). (F and G) qPCR results from senescence induction experiments, demonstrating relative mRNA levels of senescence-associated genes (see Supplemental Figure 10 for individual gene plots and statistics). N = 4–9 per cell type. (H) Cytokine analysis of conditioned media from control and D14 etoposide-treated BMSCs and macrophages. Significance was determined by multiple unpaired t tests with Holm-Šídák correction of etoposide treated versus control for each cell type. (I) SA-β-gal staining of BMSC and macrophage cultures and quantification. N = 4 per cell type. Significance was determined by 2-way ANOVA with Tukey’s multiple comparisons test. (J) Gene set enrichment analysis (GSEA) plots from RNA-seq data of control and D14 etoposide-treated BMSC and macrophage samples for the following gene sets: SenMayo, antiapoptosis (see Supplemental Table 3), and YAP/TAZ activity (CORDENONSI_YAP_CONSERVED_SIGNATURE). N = 3–4 per treatment, per cell type. (K) Raw mRNA counts of YAP/TAZ-TEAD related genes. (L and M) Predicted upstream activators in BMSCs (cGAS/STING and senescence-related) and macrophages (all) (complete data in Supplemental Table 4). SA-β-gal, senescence-associated β-galactosidase; cGAS/STING, cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts